Donate

News

Categories
Sign up to our newsletter

News

PBS approval for T-Cell lymphoma patients
published March 31, 2018
The cost of medicines to treat diabetes, cancer, arthritis, asthma and eye disease will be slashed from 1 Apri
Read more
Medicare subsidies for slow growing non-Hodgkin lymphoma
published November 8, 2017
Thousands of patients to access Medicare subsidies for life-saving treatments Among the new Medicare items are
Read more
New cancer drug boosts survival in patients with lymphoma
published October 11, 2017
Written by Lucie van den Berg, Medical reporter, Herald Sun October 5, 2017 4:02pm   A RE-ENGINEERED canc
Read more
Drug subsidy gives hope to cancer sufferers
published October 11, 2017
$187,000 to $6.30: Turnbull drug subsidy gives hope to cancer sufferersWritten by Adam Gartrell, Health C
Read more
Thanks for shining a light on lymphoma
published September 27, 2017
This is our special wrap-up of Lymphoma Awareness Month. Thank you to everyone who went lime, talked about lym
Read more
September Lymphoma News
published August 30, 2017
Catch up on the latest Lymphoma Australia news, events and lymphoma updates in our September e-news edition.&n
Read more
July Lymphoma News
published August 2, 2017
 Catch up on the latest Lymphoma Australia news, events and lymphoma updates in our July e-news edition.&
Read more
RIBOMUSTIN® has been added to the PBS
published April 27, 2016
  Rethink on chemotherapy as Government funds new medicine to fight lymphoma Thousands of Australians
Read more
PET scans help Hodgkin Lymphoma patients
published April 22, 2016
PET Determines Effectiveness of Hodgkin Lymphoma Treatment – Patients with Hodgkin lymphoma (HL) who underg
Read more
Mabthera SC approved for PBS reimbursement in Australia
published April 4, 2016
A new time-saving subcutaneous formulation of MabThera has been approved by the PBS in Australia for the treat
Read more
European Union closer to approving Nivolumab for classical Hodgkin Lymphoma
published April 1, 2016
EMA action brings Nivolumab closer to first hematology approval Click here to read more
Read more
Experts says, Study of Cutaneous T cell lymphoma likely to lead to more targeted therapies soon
published April 1, 2016
Booming knowledge of how geonomics works for Cutaneous T cell Lymphoma is likely to lead to new, more targeted
Read more
Cart
Checkout - $0.00
  • 0
  • 1

Contact Lymphoma Australia Today!

Patient Support Hotline

General Enquiries

Please note: Lymphoma Australia staff are only able to reply to emails sent in English language.

For people living in Australia, we can offer a phone translation service. Have your nurse or English speaking relative call us to arrange this.

Newsletter Sign Up

Useful Definitions

  • Refractory: This means the lymphoma does not get better with treatment. The treatment didn’t work as hoped.
  • Relapsed: This means the lymphoma came back after being gone for a while after treatment.
  • 2nd line treatment: This is the second treatment you get if the first one didn’t work (refractory) or if the lymphoma comes back (relapse).
  • 3rd line treatment: This is the third treatment you get if the second one didn’t work or the lymphoma comes back again.
  • Approved: Available in Australia and listed by the Therapeutics Goods Administration (TGA).
  • Funded: Costs are covered for Australian citizens. This means if you have a Medicare card, you shouldn’t have to pay for the treatment.[WO7]

You need healthy T-cells to make CAR T-cells. For this reason, CAR T-cell therapy cannot be used if you have a T-cell lymphoma – yet.

For more information on CAR T-cells and T-cell lymphoma click here. 

Special Note: Although your T-cells are removed from your blood for CAR T-cell therapy, most of our T-cells live outside of our blood – in our lymph nodes, thymus, spleen and other organs.